Wei Wang , Linfei Jin

Institute of Life Science, Jiyang College of Zhejiang A&F University, Zhuji, 311800, China
Author    Correspondence author
Journal of Vaccine Research, 2023, Vol. 13, No. 2   doi: 10.5376/jvr.2023.13.0002
Received: 20 Jul., 2023    Accepted: 15 Aug., 2023    Published: 25 Aug., 2023

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Wang W., and Jin L.F., 2023, Research on the history and current status of BCG vaccine, Journal of Vaccine Research, 13(2): 1-7 (doi: 10.5376/jvr.2023.13.0002)

Bacillus Calmette-Guérin (BCG) is a vaccine used to prevent tuberculosis. It is made from a live, attenuated strain of Mycobacterium bovis. When injected into the human body, it causes a mild infection that produces immunity to the human strain of the tuberculosis bacterium. The BCG vaccine is primarily used as a preventive measure against tuberculosis in children, and it generates a special resistance to the disease. To honor its inventors, French scientists Calmette and Guérin, the vaccine was named the "BCG vaccine". Currently, most countries around the world have included the BCG vaccine as one of the mandatory vaccines in their immunization programs. This study will focus on the development of the BCG vaccine, exploring its history and current status, including its relationship with pulmonary tuberculosis, research progress, vaccination methods and significance, as well as its future development.

BGC vaccine; History; Current situation; Tuberculosis (TB); Prevention